Literature DB >> 20036321

Sphingosine kinase 1 regulates the expression of proinflammatory cytokines and nitric oxide in activated microglia.

D Nayak1, Y Huo, W X T Kwang, P N Pushparaj, S D Kumar, E-A Ling, S T Dheen.   

Abstract

Microglial activation has been implicated as one of the causative factors for neuroinflammation in various neurodegenerative diseases. The sphingolipid metabolic pathway plays an important role in inflammation, cell proliferation, survival, chemotaxis, and immunity in peripheral macrophages. In this study, we demonstrate that sphingosine kinase1 (SphK1), a key enzyme of the sphingolipid metabolic pathway, and its receptors are expressed in the mouse BV2 microglial cells and SphK1 alters the expression and production of proinflammatory cytokines and nitric oxide in microglia treated with lipopolysaccharide (LPS). LPS treatment increased the SphK1 mRNA and protein expression in microglia as revealed by the RT-PCR, Western blot and immunofluorescence. Suppression of SphK1 by its inhibitor, N, N Dimethylsphingosine (DMS), or siRNA resulted in decreased mRNA expression of TNF-alpha, IL-1beta, and iNOS and release of TNF-alpha and nitric oxide (NO) in LPS-activated microglia. Moreover, addition of sphingosine 1 phosphate (S1P), a breakdown product of sphingolipid metabolism, increased the expression levels of TNF-alpha, IL-1beta and iNOS and production of TNF-alpha and NO in activated microglia. Hence to summarize, suppression of SphK1 in activated microglia inhibits the production of proinflammatory cytokines and NO and the addition of exogenous S1P to activated microglia enhances their inflammatory responses. Since the chronic proinflammatory cytokine production by microglia has been implicated in neuroinflammation, modulation of SphK1 and S1P in microglia could be looked upon as a future potential therapeutic method in the control of neuroinflammation in neurodegenerative diseases. Copyright 2010 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20036321     DOI: 10.1016/j.neuroscience.2009.12.020

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  69 in total

1.  Modulation of sphingosine 1-phosphate and tyrosine hydroxylase in the stress-induced anxiety.

Authors:  Soyong Jang; Donghyun Kim; Yeonju Lee; Sohyeon Moon; Seikwan Oh
Journal:  Neurochem Res       Date:  2010-11-13       Impact factor: 3.996

Review 2.  Targeting specific cells in the brain with nanomedicines for CNS therapies.

Authors:  Fan Zhang; Yi-An Lin; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  J Control Release       Date:  2015-12-11       Impact factor: 9.776

Review 3.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

4.  Activation of Sphingosine-1-Phosphate Receptor 1 in the Spinal Cord Produces Mechanohypersensitivity Through the Activation of Inflammasome and IL-1β Pathway.

Authors:  Timothy M Doyle; Zhoumou Chen; Mariaconcetta Durante; Daniela Salvemini
Journal:  J Pain       Date:  2019-02-23       Impact factor: 5.820

5.  Periodontal inflammation and alveolar bone loss induced by Aggregatibacter actinomycetemcomitans is attenuated in sphingosine kinase 1-deficient mice.

Authors:  H Yu; C Sun; K M Argraves
Journal:  J Periodontal Res       Date:  2015-04-20       Impact factor: 4.419

6.  Sphingosine kinase 1 inhibition improves lipopolysaccharide/D-galactosamine-induced acute liver failure by inhibiting mitogen-activated protein kinases pathway.

Authors:  Tao Tian; Weiliang Tian; Fan Yang; Risheng Zhao; Qian Huang; Yunzhao Zhao
Journal:  United European Gastroenterol J       Date:  2016-03-02       Impact factor: 4.623

Review 7.  Targeting Sphingosine Kinases for the Treatment of Cancer.

Authors:  Clayton S Lewis; Christina Voelkel-Johnson; Charles D Smith
Journal:  Adv Cancer Res       Date:  2018-06-09       Impact factor: 6.242

Review 8.  Sphingolipids in spinal cord injury.

Authors:  Zachary B Jones; Yi Ren
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2016-08-05

Review 9.  Sphingolipids in neurodegeneration (with focus on ceramide and S1P).

Authors:  Guanghu Wang; Erhard Bieberich
Journal:  Adv Biol Regul       Date:  2018-09-22

10.  Activation of ATP secretion via volume-regulated anion channels by sphingosine-1-phosphate in RAW macrophages.

Authors:  Philipp Burow; Manuela Klapperstück; Fritz Markwardt
Journal:  Pflugers Arch       Date:  2014-06-26       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.